Evidence map›Paper›PMID 32259070›Full record

ArticleACS pharmacology & translational science2019

Genome-Wide RNAi Screen Identifies Regulators of Cardiomyocyte Necrosis.

Zhaokang Cheng, Matthew Combs, Qiang Zhu, Peng Xia, Zachary Opheim, Joel Parker, Christopher P Mack, Joan M Taylor

Open access · greenAbstract read
In one paragraph

Article in ACS pharmacology & translational science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Innovation and Discovery in Cardiovascular Biology.ACS pharmacology & translational science · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhaokang ChengDepartment of Pharmaceutical Sciences, Washington State University, Spokane, Washington 99210, United States.
Matthew CombsDepartment of Pathology, Department of Genetics, Lineberger Cancer Center, and McAllister Heart Institute, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Qiang ZhuDepartment of Pathology, Department of Genetics, Lineberger Cancer Center, and McAllister Heart Institute, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Peng XiaDepartment of Pharmaceutical Sciences, Washington State University, Spokane, Washington 99210, United States.
Zachary OpheimDepartment of Pathology, Department of Genetics, Lineberger Cancer Center, and McAllister Heart Institute, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Joel ParkerDepartment of Pathology, Department of Genetics, Lineberger Cancer Center, and McAllister Heart Institute, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Christopher P MackDepartment of Pathology, Department of Genetics, Lineberger Cancer Center, and McAllister Heart Institute, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Joan M TaylorDepartment of Pathology, Department of Genetics, Lineberger Cancer Center, and McAllister Heart Institute, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
University of North Carolina at Chapel Hill · USWashington State University Spokane · US

Funding

Role of The Rho-GAP GRAF3 In The Pathogenesis of Human HypertensionR01HL130367 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MACK, CHRISTOPHER P., TAYLOR, JOAN M · 2016 to 2019
$2.9M
FAK Signaling in cardiac growth and hypertrophyR01HL081844 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TAYLOR, JOAN M · 2005 to 2013
$2.6M
Molecular Control of Cardiomyocyte Mitophagy by the RhoGAP GRAF1R01HL142879 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TAYLOR, JOAN M · 2020 to 2023
$1.8M
Adhesion Signaling in Vascular Growth and DevelopmentR01HL071054 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TAYLOR, JOAN M. · 2003 to 2006
$1.2M
Promoting chemoresistance in the heartR00HL119605 · NHLBI · WASHINGTON STATE UNIVERSITY · PI CHENG, ZHAOKANG · 2016 to 2018
$747k
NHLBI NIH HHS R00 HL119605NHLBI NIH HHS R01 HL071054NHLBI NIH HHS R01 HL081844NHLBI NIH HHS R01 HL130367NHLBI NIH HHS R01 HL142879
6 · The paper itself

Abstract

Regulation of cellular death is central to nearly all physiological routines and is dysregulated in virtually all diseases. Cell death occurs by two major processes, necrosis which culminates in a pervasive inflammatory response and apoptosis which is largely immunologically inert. As necrosis has long been considered an accidental, unregulated form of cellular death that occurred in response to a harsh environmental stimulus, it was largely ignored as a clinical target. However, recent elegant studies suggest that certain forms of necrosis can be reprogrammed. However, scant little is known about the molecules and pathways that orchestrate calcium-overload-induced necrosis, a main mediator of ischemia/reperfusion (IR)-induced cardiomyocyte cell death. To rectify this critical gap in our knowledge, we performed a novel genome-wide siRNA screen to identify modulators of calcium-induced necrosis in human muscle cells. Our screen identified multiple molecular circuitries that either enhance or inhibit this process, including lysosomal calcium channel TPCN1, mitophagy mediatorTOMM7, Ran-binding protein RanBP9, Histone deacetylase HDAC2, chemokine CCL11, and the Arp2/3 complex regulator glia maturation factor-γ (GMFG). Notably, a number of druggable enzymes were identified, including the proteasome β5 subunit (encoded by PSMB5 gene), which controls the proteasomal chymotrypsin-like peptidase activity. Such findings open up the possibility for the discovery of pharmacological interventions that could provide therapeutic benefits to patients affected by myriad disorders characterized by excessive (or too little) necrotic cell loss, including but not limited to IR injury in the heart and kidney, chronic neurodegenerative disorders, muscular dystrophies, sepsis, and cancers.

Identifiers

PMID32259070
PMCPMC7088983
OpenAlexW2971984659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.